OakChart

Codexis Inc

CDXSHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 1:05 PM ET

0.9871-0.0129 (-1.29%)
2026-11-11 19:05 CET
Market cap
109.51 USD m
Revenue, TTM
77.68 USD m
Net income, TTM
-30.72 USD m
Free cash flow, TTM
-12.18 USD m
EPS diluted, TTM
-0.34
P/E
-
Compare

Price

CDXS against its 20, 50 and 200-day averages
2050200beatearnings
1.001.502.002.503.005.2M10.4MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CDXSclose 0.9920-day 1.1850-day 1.31200-day 1.790.9952w high

66.9% under the 52-week high of 2.98 on 11 May 2026. 52-week low 0.95 on 11 Nov 2026. Last 15 sessions, 40.0% high to low

Profile

CDXS
52-week range, 1% of the way up
0.962.98

Codexis, Inc. is an enzyme engineering company, which engages in technology solutions to improve therapeutics manufacturing. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.

IndexRUT
Employees146
IPOApr 22, 2010
Beta2.41
ATR, 14d0.09
Rel volume1.18
Short float4.32%
Insider own7.10%
Inst own64.14%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap108.10M
Enterprise Value125.35M
Income-30.72M
Sales77.68M
Book/sh0.36
Cash/sh0.51
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees146
IPOApr 22, 2010

Ratios

P/E-
Forward P/E-
PEG-
P/S1.39
P/B2.74
P/C1.95
P/FCF-
EV/EBITDA-
EV/Sales1.61
Quick Ratio2.99
Current Ratio3.06
Debt/Eq2.20
LT Debt/Eq1.89
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.34
EPS next Y-0.28
EPS next Q-0.10
EPS this Y24.86%
EPS next Y26.36%
EPS next 5Y39.03%
EPS past 3/5Y0.62% -4.52%
Sales past 3/5Y-20.22% 0.38%
EPS Y/Y TTM58.70%
Sales Y/Y TTM35.89%
EPS Q/Q15.19%
Sales Q/Q-2.69%
EarningsNov 12 AMC
EPS/Sales Surpr.8.26% 7.89%

Ownership

Insider Own7.10%
Insider Trans-0.21%
Inst Own64.14%
Inst Trans2.75%
ROA-23.79%
ROE-69.36%
ROIC-32.27%
Gross Margin80.47%
Oper. Margin-31.23%
Profit Margin-39.55%
SMA20-16.64%
SMA50-24.43%
SMA200-44.96%
Trades-

Technical

Shs Outstand109.51M
Shs Float101.73M
Short Float4.32%
Short Ratio4.86
Short Interest4.40M
52W High2.98 -66.88%
52W Low0.96 3.01%
Volatility9.46% 7.75%
ATR (14)0.09
RSI (14)32.75
Beta2.41
Rel Volume1.18
Avg Volume904.29K
Volume614,208

Performance

Perf Week-8.60%
Perf Month-25.22%
Perf Quarter-38.31%
Perf Half Y-60.52%
Perf YTD-39.44%
Perf Year-45.16%
Perf 3Y-40.54%
Perf 5Y-97.37%
Perf 10Y-80.83%
Recom1.50
Target Price6.14
Prev Close1.00
Price0.99
Change %-1.29%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Aug 19, 2024DowngradeTThe Benchmark CompanyBuy → Hold
Jun 03, 2024ResumedJJefferiesBuy$5+406.5%
May 30, 2024InitiatedCCantor FitzgeraldOverweight$11+1,014.4%
Feb 29, 2024UpgradeTThe Benchmark CompanyHold → Buy
Nov 07, 2023DowngradeTThe Benchmark CompanyBuy → Hold
Aug 07, 2023DowngradeTTD CowenOutperform → Market Perform$21 → $4+305.2%
May 09, 2023DowngradeHH.C. WainwrightBuy → Neutral
Mar 31, 2022ResumedPPiper SandlerOverweight$35+3,445.7%
Mar 02, 2022ResumedCCowenOutperform
Apr 12, 2021InitiatedPPiper SandlerOverweight$32+3,141.8%

Peers

Mkt cap
TickerCompanyMkt cap
MRVIMaravai LifeSciences Holdings Inc2.06B
DNAGinkgo Bioworks Holdings Inc749.10M
TWSTTwist Bioscience Corp8.87B
CBUSCibus Inc90.95M
AAgilent Technologies Inc50.35B
ABSIAbsci Corp1.74B
SEERSeer Inc89.15M
TECHBio-Techne Corp11.43B
TKNOAlpha Teknova Inc553.86M
DHRDanaher Corp165.97B

Insider trading

latest 14 of 22
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
De Vre RaymondDirectorNov 09 '26Sale1.111,0881,20883,723Nov 10 04:05 PM
Erbez GeorgiaSee RemarksOct 12 '26Sale1.366,3358,61960,475Oct 14 05:19 PM
MOORE ALISONPresident and CEOOct 12 '26Sale1.366,3358,619244,171Oct 14 05:17 PM
Erbez GeorgiaOfficerOct 12 '26Proposed Sale1.366,3358,619Oct 13 04:32 PM
MOORE ALISONOfficerOct 12 '26Proposed Sale1.366,3358,619Oct 13 04:27 PM
De Vre RaymondDirectorJun 11 '26Sale2.372,6056,17484,811Jun 11 08:19 PM
Lutz StefanChief Scientific OfficerFeb 24 '26Sale1.135,8626,641130,421Feb 25 07:54 PM
Lutz StefanOfficerFeb 24 '26Proposed Sale1.175,2806,178Feb 23 08:08 PM
Lutz StefanChief Scientific OfficerFeb 06 '26Sale1.312,4923,257136,283Feb 09 04:07 PM
Erbez GeorgiaSee RemarksFeb 06 '26Sale1.313,8265,00166,810Feb 09 04:07 PM
MOORE ALISONPresident and CEOFeb 06 '26Sale1.313,8265,001250,506Feb 09 04:06 PM
Norrett KevinOfficerFeb 06 '26Proposed Sale1.273,2914,180Feb 06 06:18 PM
Lutz StefanOfficerFeb 06 '26Proposed Sale1.272,4603,124Feb 06 06:15 PM
KEVIN NORRETTOfficerJan 16 '26Proposed Sale1.671,7452,914Jan 16 05:09 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B

News

latest 14 of 206
  • Codexis Enters into $60 Million Term Loan Facility with Trinity Capital (GlobeNewswire) -9.91%
  • Codexis Advances ECO Synthesis Toward Adoption Readiness with Quality at Scale and Expanded siRNA Manufacturing Capabilities (GlobeNewswire)
  • Codexis Needs A Third-Quarter Revenue Jump To Back Its Back-Loaded 2026 Plan (Earnings Whispers) -5.56%
  • Codexis to Report Third Quarter 2026 Financial Results on November 12 (GlobeNewswire)
  • Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA (GlobeNewswire)
  • Loading…
  • What Needs To Be True To Buy Twist Bioscience Stock Now? (Trefis)
  • Codexis to Participate in Cantor Global Healthcare Conference 2026 (GlobeNewswire)
  • Codexis Inc (CDXS) (Q2 2026) Earnings Call Highlights: Biocatalysis Growth and ECO Synthesis ... (GuruFocus.com) +8.11%
  • Codexis: Q2 Earnings Snapshot (Associated Press)
  • Codexis Reports Second Quarter 2026 Financial Results (GlobeNewswire)
  • Codexis Appoints David Butler, PhD, to Strategic Advisory Board (GlobeNewswire)
  • Codexis to Report Second Quarter 2026 Financial Results on August 11 (GlobeNewswire)
  • Codexis Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -25.63%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--0.096--18.727
2026Q22026-08-11-0.130-0.142-0.13014.9213.826
2026Q12026-05-07-0.100-0.137-0.09615.2514.536
2025Q42026-03-110.110-0.0300.10638.9235.836
2025Q32025-11-06-0.220-0.149-0.2178.6018.517
2025Q22025-08-13-0.160-0.189-0.15515.3314.097
2025Q12025-05-14-0.250-0.237-0.2517.549.677
2024Q42025-02-27-0.130-0.036-0.12821.4627.418
2024Q32024-10-31-0.290-0.239-0.28712.8311.498
2024Q22024-08-08-0.320-0.264-0.3237.987.828
2024Q12024-05-02-0.160-0.180-0.16517.0713.317
2023Q42024-02-28-0.100-0.124-0.10426.5619.907
2023Q32023-11-02-0.500-0.324-0.5039.2810.037
2023Q22023-08-03-0.170-0.214-0.17121.3219.838
2023Q12023-05-04-0.340-0.309-0.34312.9814.098
2022Q42023-02-23-0.190-0.226-0.19230.3828.938

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.060-0.113-0.21168.4671.24
2020FY-0.400-0.347-0.40569.0668.90
2021FY-0.330-0.384-0.330104.75103.44
2022FY-0.510-0.548-0.514138.59137.14
2023FY-1.120-1.149-1.11970.1463.47
2024FY-0.890-0.794-0.88959.3565.29
2025FY-0.500-0.640-0.50070.3967.28
2026FY--0.376--73.88
2027FY--0.277--87.69
2028FY--0.113--111.15
2029FY-0.070--139.17
2030FY-0.190--166.07

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-0180018.7215.3621.20
2026Q3S2026-10-2881018.7215.3621.20
2026Q3S2026-10-2681118.7215.3621.20
2026Q3S2026-10-2281418.7215.3621.20
2026Q3S2026-10-1981418.7315.3621.20
2026Q3S2026-09-1881418.7315.3621.20
2026Q3S2026-08-1871418.6215.3621.20
2026Q3S2026-08-1470418.3315.3621.20
2026Q3S2026-08-1270318.9315.3621.93
2026Q3S2026-08-1170019.5717.0821.93
2026Q3S2026-07-2270019.5717.0821.93
2026Q3S2026-06-1272019.5717.0821.93
2026Q3S2026-05-2673019.5717.0821.93
2026Q3S2026-05-0874019.5717.0821.93

Estimate history

EPS, annual-0.497-0.208-0.211-0.405-0.33-0.514-1.119-0.889-0.505-0.3395
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.323-0.287-0.128-0.251-0.155-0.2170.106-0.096-0.132
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual50.02460.59468.45869.056104.754138.5970.14359.34570.38777.68
Period201720182019202020212022202320242025TTM
Sales, quarterly7.97912.83321.467.54315.3288.60138.91515.24814.915
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual48.36554.06558.87764.28365.10965.81169.90581.8590.47891.388
Period201720182019202020212022202320242025MRQ
Shares, quarterly70.91481.37681.8582.84190.25490.28190.47890.89491.388
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue77.6870.3959.3470.14138.59104.7569.0668.4660.59
Cost of Goods Sold Incl. D&A15.1714.4421.1318.3343.4425.3215.6917.4113.77
Gross Profit62.5155.9538.2151.8295.1679.4353.3651.0546.83
Selling, General and Administrative Excl. Other86.7794.2896.57106.62126.87102.1377.2863.6058.12
Research and Development44.5248.1842.3058.8880.1055.9244.1932.7529.11
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-24.26-38.33-58.35-54.80-31.71-22.70-23.92-12.55-11.29
Interest Expense---0.000.000.000.00--
Unusual Expense3.413.717.0725.472.97-1.000.000.500.08
Net Income Before Taxes-30.65-43.93-65.24-76.17-33.32-21.09-23.67-11.92-10.91
Income Taxes0.070.050.030.070.280.190.340.02-0.04
Consolidated Net Income-30.72-43.97-65.28-76.24-33.59-21.28-24.01-11.94-10.88
Net Income From Continuing Operations-30.72-43.97-65.28-76.24-33.59-21.28-24.01-11.94-10.88
Net Income-30.72-43.97-65.28-76.24-33.59-21.28-24.01-11.94-10.88
EPS (Recurring)-0.31-0.47-0.82-0.86-0.48-0.34-0.40-0.20-0.21
EPS (Basic, Before Extraordinaries)-0.34-0.50-0.89-1.12-0.51-0.33-0.40-0.21-0.21
EPS (Diluted)-0.34-0.50-0.89-1.12-0.51-0.33-0.40-0.21-0.21
EBITDA-15.60-30.04-50.22-44.88-21.46-16.75-19.37-7.78-10.15
Non-Operating Income (Expense)-1.69-1.890.184.101.360.610.251.130.46
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense6.107.6010.347.8811.488.465.565.076.23
Price To Sales Ratio2.652.025.902.962.2019.2718.7613.2014.39
Gross Margin80.4779.4964.3973.8768.6675.8377.2874.5777.28
Operating Margin-31.23-54.46-98.33-78.13-22.88-21.67-34.64-18.33-18.64
Net Margin-39.55-62.47-109.99-108.69-24.24-20.31-34.77-17.43-17.95
Shares Outstanding91.3990.4881.8569.9165.8165.1164.2858.8854.06
Market Capitalization109.51109.51388.17212.98306.102,028.651,387.68935.70902.07

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue14.9115.2538.918.6015.337.5421.4612.83
Cost of Goods Sold Incl. D&A4.713.313.363.783.403.894.825.50
Gross Profit10.2111.9435.554.8211.933.6516.647.33
Selling, General and Administrative Excl. Other21.4319.9821.5923.7724.7924.1423.9823.89
Research and Development10.6210.3110.9212.6712.5912.0011.1510.54
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-11.23-8.0413.96-18.95-12.86-20.49-7.34-16.56
Interest Expense1.30-------
Unusual Expense0.000.003.410.000.00-3.000.00
Net Income Before Taxes-11.99-8.679.62-19.61-13.26-20.68-10.37-20.63
Income Taxes0.010.040.020.010.010.010.000.01
Consolidated Net Income-12.01-8.709.60-19.61-13.27-20.69-10.38-20.64
Net Income From Continuing Operations-12.01-8.709.60-19.61-13.27-20.69-10.38-20.64
Net Income-12.01-8.709.60-19.61-13.27-20.69-10.38-20.64
EPS (Recurring)-0.13-0.100.13-0.22-0.16-0.25-0.10-0.29
EPS (Basic, Before Extraordinaries)-0.13-0.100.11-0.22-0.16-0.25-0.13-0.29
EPS (Diluted)-0.13-0.100.11-0.22-0.16-0.25-0.13-0.29
EBITDA-9.07-5.8216.19-16.89-10.83-18.58-5.25-14.57
Non-Operating Income (Expense)0.54-0.62-0.94-0.66-0.40-0.19-0.03-4.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.251.131.741.992.001.882.002.14
Price To Sales Ratio2.651.892.114.163.644.456.533.44
Gross Margin68.4278.2891.3656.0277.8248.4377.5257.13
Operating Margin-75.29-52.7535.89-220.31-83.91-271.59-34.21-129.02
Net Margin-80.49-57.0824.67-228.05-86.59-274.27-48.35-160.84
Shares Outstanding91.3990.8990.4890.2890.2582.8481.8581.38
Market Capitalization109.51148.12147.23220.25202.14222.83388.17218.46

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments78.6973.9665.64114.50117.38150.7591.1653.0431.22
Short Term Receivables10.6918.8819.9340.8737.6529.2920.1613.5011.80
Inventories1.821.802.692.031.160.960.370.591.04
Other Current Assets5.634.135.225.495.703.422.521.070.98
Total Current Assets96.8298.7793.47162.89161.89184.42114.2068.2045.04
Net Property, Plant & Equipment43.5242.9028.6261.8865.4631.1830.394.762.81
Total Investments and Advances4.113.8610.7622.0315.522.511.062.032.23
Long-Term Note Receivable0.300.50-------
Intangible Assets2.462.462.463.243.243.243.243.243.24
Other Assets0.580.521.250.350.280.290.181.050.30
Total Assets147.80149.01136.56250.39246.38221.65149.0779.2853.62
Short Term Debt Incl. Current Port. of LT Debt2.942.8310.125.364.092.631.170.000.00
Accounts Payable1.552.845.953.253.002.972.623.053.54
Other Current Liabilities20.8217.9819.7640.4626.2819.3811.6015.0621.41
Total Current Liabilities25.3223.6535.8349.0733.3724.9815.3918.1124.95
Long Term Debt70.2657.0712.2438.2843.5622.3224.950.060.30
Provision for Risks Charges0.300.300.300.500.400.200.200.200.20
Other Liabilities1.391.071.5717.754.664.043.024.603.62
Total Liabilities97.2782.0849.95105.6081.9951.5443.5622.9829.08
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity50.5366.9386.61144.80164.39170.10105.5256.3124.55
Total Shareholders Equity50.5366.9386.61144.80164.39170.10105.5256.3124.55
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity50.5366.9386.61144.80164.39170.10105.5256.3124.55
Total Liabilities & Stockholders Equity147.80149.01136.56250.39246.38221.65149.0779.2853.62
Book Value Per Share0.560.821.242.202.522.651.791.040.51
Tangible Book Value Per Share0.530.791.202.152.482.601.740.980.44
Full-Time Employees146188174248261181161132116
Price to Book Ratio2.775.292.331.9812.388.258.9216.0418.27
Return on Assets-29.63-45.72-39.41-13.52-9.09-12.95-10.45-16.37-51.52
Return on Equity-74.88-85.03-65.89-21.73-12.72-17.42-14.75-26.91-105.38
Return on Invested Capital-36.40-52.64-77.12-18.35-10.23-12.48-9.15-19.30-92.54
Quick Ratio3.754.102.533.284.827.347.403.731.76
Current Ratio3.824.182.613.324.857.387.423.771.81

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-30.72-43.97-65.28-76.24-33.59-21.28-24.01-11.94-10.88
Depreciation8.708.298.139.9210.255.954.554.561.15
Other Funds (Non Cash)8.439.8919.7531.9013.058.696.887.477.98
Funds from Operations-13.60-25.79-37.39-34.42-10.29-6.64-12.570.09-1.75
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital3.206.42-12.02-18.2221.57-7.62-3.89-12.65-12.34
Cash from Operating Activities-10.40-19.38-49.41-52.6411.28-14.27-16.46-12.56-14.09
Capital Expenditures-1.78-4.47-4.30-4.42-8.31-13.83-3.75-3.73-2.77
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.020.010.090.750.030.040.000.000.00
Purchase or Sale of Investments12.9227.97-52.76-1.19-5.30-7.63-2.000.060.00
Purchase of Investments-65.94-57.16-90.23-1.19-5.30-7.63-2.000.000.00
Sale Or Maturity of Investments78.8785.1337.47-0.000.000.000.060.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities11.1623.50-56.98-4.86-13.58-21.42-5.75-3.67-2.77
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.1218.0331.648.570.914.9782.1256.9842.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.1218.0331.648.570.914.9782.1256.9842.00
Proceedsfrom Stock Options0.1216.9430.26-0.50-0.04-0.2180.8049.8837.32
Issuance or Reduction of Debt, Net0.009.8928.880.000.000.00-0.06-0.24-0.24
Change in Long Term Debt0.009.8928.880.000.000.00-0.06-0.24-0.24
Issuance of Long Term Debt0.009.8928.880.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00-0.06-0.24-0.24
Net Financing Active Other Cash Flow0.000.000.00-0.40-1.49-1.21-1.26-2.77-3.19
Other Financing Activities Uses0.000.000.00-0.40-1.49-1.21-1.26-2.85-3.19
Cash from Financing Activities0.1227.9360.528.17-0.573.7780.8153.9638.57
Net Change in Cash0.8832.05-45.87-49.33-2.87-31.9258.6037.7421.71
Free Cash Flow-12.18-23.85-53.72-57.062.98-28.09-20.21-16.29-16.86
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow----102.29----
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments55.3465.5678.6959.1966.8360.28
Short Term Receivables11.658.0310.699.7316.4811.59
Inventories1.602.001.821.941.951.78
Other Current Assets3.334.065.635.343.474.16
Total Current Assets71.9279.6596.8276.1988.7377.81
Net Property, Plant & Equipment40.5242.1543.5240.5342.2443.79
Total Investments and Advances4.114.114.113.863.863.86
Intangible Assets2.462.462.462.462.462.46
Other Assets0.440.590.580.510.650.57
Total Assets120.06129.37147.80123.96138.25128.89
Short Term Debt Incl. Current Port. of LT Debt10.353.302.943.093.002.91
Accounts Payable2.612.131.552.421.476.05
Other Current Liabilities10.559.4220.8212.9610.7711.94
Total Current Liabilities23.5114.8525.3218.4815.2420.90
Long Term Debt62.2469.6070.2665.5365.9856.58
Provision for Risks Charges0.000.000.300.000.000.00
Other Liabilities1.351.691.391.411.401.77
Total Liabilities87.1086.1497.2785.4282.6179.26
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity32.9643.2350.5338.5455.6349.63
Total Shareholders Equity32.9643.2350.5338.5455.6349.63
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity32.9643.2350.5338.5455.6349.63
Total Liabilities & Stockholders Equity120.06129.37147.80123.96138.25128.89
Book Value Per Share0.360.480.560.430.620.60
Tangible Book Value Per Share0.330.450.530.400.590.57
Full-Time Employees--146---
Price to Book Ratio2.772.923.823.964.073.29
Return on Assets-23.79-24.77-29.63-47.00-48.09-53.48
Return on Equity-69.36-68.90-74.88-114.26-111.00-115.53
Return on Invested Capital-12.61-7.717.95-18.85-10.91-19.48
Quick Ratio2.995.233.754.025.703.64
Current Ratio3.065.363.824.125.823.72

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-12.01-8.709.60-19.61-13.27-20.69
Depreciation2.162.222.222.092.071.91
Other Funds (Non Cash)1.751.572.582.542.562.21
Funds from Operations-8.10-4.9214.40-14.98-8.65-16.57
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.54-8.235.697.28-9.322.77
Cash from Operating Activities-9.64-13.1520.09-7.70-17.97-13.80
Capital Expenditures-0.90-0.18-0.52-0.18-2.51-1.26
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.010.000.000.000.000.00
Purchase or Sale of Investments1.06-0.936.236.572.1413.02
Purchase of Investments-12.94-20.02-15.27-17.71-13.86-10.33
Sale Or Maturity of Investments14.0019.0921.5024.2816.0023.35
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.17-1.115.716.39-0.3711.77
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.07-0.010.18-0.1116.881.08
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.07-0.010.18-0.1116.881.08
Proceedsfrom Stock Options0.07-0.010.18-0.1116.88-0.01
Issuance or Reduction of Debt, Net0.000.000.000.009.890.00
Change in Long Term Debt0.000.000.000.009.890.00
Issuance of Long Term Debt0.000.000.000.009.890.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.07-0.010.18-0.1126.771.08
Net Change in Cash-9.40-14.2825.98-1.438.44-0.94
Free Cash Flow-10.54-13.3319.57-7.88-20.48-15.05

Revenue breakdown

Product2024: 36.79M 2025: 26.03M
Research And Development2024: 22.56M 2025: 44.36M
Americas2024: 21.28M 2025: 43.54M
Asia Pacific2024: 27.71M 2025: 17.56M
EMEA2024: 10.36M 2025: 9.29M
Total Industrial Organic Chemicals revenue2024: 59.35M 2025: 70.39M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.32%4.4M101.7M937.71K
2026-10-154.87%5.0M101.7M1.12M
2026-09-304.76%4.8M101.7M1.12M
2026-09-153.96%4.0M101.7M1.14M
2026-08-313.78%3.8M101.7M1.14M
2026-08-143.67%3.7M101.6M1.09M
2026-07-313.94%3.9M99.6M1.12M
2026-07-154.45%3.7M84.2M992.45K
2026-06-303.84%3.2M84.2M1.13M
2026-06-153.87%3.3M84.2M1.24M
2026-05-294.61%3.9M84.2M2.28M
2026-05-154.39%3.7M84.2M2.34M
2026-04-305.56%4.7M84.2M2.37M
2026-04-157.51%6.3M83.6M2.37M
2026-03-317.88%6.9M88.1M2.20M
2026-03-1312.22%10.8M88.1M2.12M
2026-02-2710.46%9.2M87.6M1.10M
2026-02-138.29%7.3M87.6M1.07M
2026-01-307.36%6.4M87.6M1.16M
2026-01-156.77%5.9M87.6M1.06M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.150.900.0019.3040.000.000.959-0.0150.000
call1.000.000.500.508.7492225.000.814-0.0270.000
call1.500.000.150.214.6142.000.000.416-0.0160.001
call2.000.000.950.005.7640.000.000.373-0.0190.001
call2.500.000.600.006.5590.000.000.350-0.0210.001
call5.000.000.750.0016.4690.000.000.750-0.0450.000
call7.500.000.750.0017.5420.000.000.742-0.0480.000
put0.500.001.000.000.0000.000.00-0.037-0.0140.000
put1.000.000.750.1014.65834.000.00-0.186-0.0260.000
put1.500.200.900.558.58549.000.00-0.584-0.0150.001
put2.000.701.400.009.7340.000.00-0.627-0.0190.001
put2.501.201.900.0010.5440.000.00-0.650-0.0210.001
put5.003.404.600.0016.3420.000.00-0.693-0.0260.001
put7.505.807.300.0022.3730.000.00-0.708-0.0280.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-104Statement of changes in beneficial ownership of securities2026-11-09SEC
2026-11-108-KCurrent report2026-11-05SEC
2026-11-06SCHEDULE 13G/ASEC
2026-10-30SCHEDULE 13G/ASEC
2026-10-144Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-10-144Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-10-13144Filing for proposed sale of securities under Rule 144.SEC
2026-10-13144Filing for proposed sale of securities under Rule 144.SEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-07-29SCHEDULE 13GSEC
2026-07-278-KCurrent report2026-07-23SEC
2026-07-24424B5SEC
2026-07-23424B5SEC
2026-07-238-KCurrent report2026-07-23SEC
2026-07-20SCHEDULE 13G/ASEC
2026-06-228-KCurrent report2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-184Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-05-05SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-11001.21K1
2026-100017.24K2
2026-090000
2026-080000
2026-070000
2026-06006.17K1
2026-050000
2026-040000
2026-030000
2026-020019.90K4
2026-01007.95K1
2025-1200422.77K1
2025-11001.95M8

Institutional holders

Manager% owned
Aberdeen Group plc9.86%
BlackRock, Inc.8.01%
Nantahala Capital Management, LLC7.97%
Opaleye Management Inc.7.46%
Telemark Asset Management, LLC7.17%
MILLENNIUM MANAGEMENT LLC6.10%
AMERIPRISE FINANCIAL INC4.19%
VANGUARD CAPITAL MANAGEMENT LLC3.98%
GEODE CAPITAL MANAGEMENT, LLC2.26%
STATE STREET CORP1.93%

Funds

Fund% owned
abrdn Healthcare Investors4.88%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.90%
abrdn Life Sciences Investors2.57%
iShares Russell 2000 ETF2.52%
Columbia Small Cap Value Discovery Fund2.47%
VANGUARD EXTENDED MARKET INDEX FUND0.99%
Fidelity Small Cap Index Fund0.88%
iShares Russell 2000 Growth ETF0.77%
iShares Biotechnology ETF0.65%
Columbia Variable Portfolio - Small Cap Value Discovery Fund0.53%

OakChart. CDXS. Cached 15 minutes.